Inside these posts: Breast cancer

Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.


Neopharm narrows losses but needs new funding

Lake Bluff biotech company Neopharm Inc. said Thursday that it had narrowed its losses in both the second quarter and first half of this year and reported progress in clinical trials for its breast, pancreatic and prostate cancer drugs.

But Aquilur Rahman, president and chief executive officer, warned that with cash dwindling to $1.8 million as of June 30, the company needs new funding to continue. Get the full story »

FDA questions Roche’s Avastin for breast cancer

The Food and Drug Administration questioned the benefit of using Roche Holding AG’s  top-selling cancer drug, Avastin, in breast cancer.

The agency said the magnitude of an improvement seen among women being treated with chemotherapy drugs plus Avastin compared with women being given chemotherapy alone “is not clinically meaningful.” The agency also said there were more serious side effects such as bleeding seen among women being given Avastin. Get the full story »

APP to market breast cancer treatment

Schaumburg-based APP Pharmaceuticals Inc. will begin marketing a breast cancer treatment medication in the U.S. as Anastrozole, the drug’s generic name. Anastrozole tablets, also known as Arimidex , are mainly used to treat early breast cancer in post-menopausal women.

APP’s parent company, Fresenius Kabi Pharmaceuticals Holding Inc., said the move comes after the U.S. Food and Drug Administration granted its research company permission to market the drug.